GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biophytis SA (XPAR:ALBPS) » Definitions » Valuation Rank

Biophytis (XPAR:ALBPS) Valuation Rank


View and export this data going back to 2015. Start your Free Trial

What is Biophytis Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Biophytis Valuation Rank Related Terms

Thank you for viewing the detailed overview of Biophytis's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Biophytis (XPAR:ALBPS) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biophytis SA (XPAR:ALBPS) » Definitions » Valuation Rank
Comparable Companies
XPAR:ALVET XPAR:ALMDP XPAR:ALQGC XPAR:ALTME XPAR:ALINT XPAR:ALPAT XPAR:ALTHX XPAR:ALNFL XPAR:ALNEV XPAR:ALPHA OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
BPTSY:USA 0D1W:UK 6XB3:Germany
Address
BC 9, Batiment A 4eme etage, 4 pace Jussieu, Sorbonne University, Paris, FRA, 75005
Website
https://www.biophytis.com
Biophytis SA is a France-based biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging and improve functional outcomes for patients suffering from age-related diseases. Its drug candidate, Sarconeos (BIO101), is an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and DMD.